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Joann A. Boughman, PhD* Kyle M. Brown, PhD** 
 
The Geneticists’ Approach to Bilski 
THE PATENT PROCESS AND ITS ASSOCIATED CASE LAW HAVE become increasing familiar 
to genetic research scientists and medical geneticists.1 For example, nearly 
1% (19 of 3100) of researchers who applied to present research at the 2011 
annual meeting of the American Society for Human Genetics reported a 
possible or perceived financial conflict of interest based on their intellectual 
property holdings.2 Guided by the interests of their members, professional 
organizations of geneticists, like the American Society of Human Genetics 
(ASHG) and others, have become responsive to and involved in the legal 
processes involved with intellectual property protection.3 In Bilski v. 
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 1. See generally Alex Osterlind, Staking a Claim on the Building Blocks of Life: Human 
Genetic Material within the United States Patent System, 75 MO. L. REV. 617 (2010) (discussing 
the patentability of genetic material); D. Benjamin Borson, The Human Genome Projects: 
Patenting Human Genes and Biotechnology. Is the Human Genome Patentable?, 35 IDEA 461, 
461 (1995) (analyzing the legal issues surrounding patent protection of the products of studies of 
the human genome).  For additional information on genetic patents, see DAVID B. RESNIK, 
OWNING THE GENOME: A MORAL ANALYSIS OF DNA PATENTING 50–55 (2004). 
 2.  American Society of Human Genetics, 60th Annual Meeting Program, 361–63 (2010), 
http://www.ashg.org/2010meeting/pdf/ASHG_program.pdf.  
 3. See, e.g., Brief for American Society of Human Genetics et al. as Amici Curiae 
Supporting  Plaintiffs’ Opposition to Defendants’ Motion To Dismiss and Supporting Plaintiffs’ 
Motion for Summary Judgment at 6, Ass’n for Molecular Pathology, et al. v. United States Patent 
and Trademark Office, et al., 702 F.Supp.2d 181 (2009) (No. 09 Civ. 4515), 2009 WL 3269106 
(S.D.N.Y.); Brief for The American College of Medical Genetics, et al. as Amici Curiae 
Supporting Respondents at 1, Bilski v. Kappos, 130 S. Ct. 3218 (2010). 
      
T G’ A  B 
60   JOURNAL OF BUSINESS & TECHNOLOGY LAW 
 
Kappos,4 the Supreme Court ruled on the patentability of certain subject 
matter for the first time in 30 years.5 The ruling has potential implications 
for a variety of patentable “arts,” including medical and research genetics, 
but the narrow scope of this ruling, in conjunction with other decisions, has 
left significant uncertainty in the field of human genetics about what 
constitutes patentable material.6 
In order to continue producing innovative research and discoveries that 
will contribute to the treatment of disease, genetics researchers need more 
legal certainty about the patentability of genetic methods and materials.7 By 
applying a current understanding of medical and research genetics to 
questions of patentability, courts will be able to resolve ambiguities in 
patent jurisprudence while stimulating innovation and access to the benefits 
of genetically informed medicine.8  
The genetics community has taken a balanced approach, embracing the 
protection of intellectual property while fostering openness in research.9 
However, recent court decisions and patent office precedents defy the 
original intent of the patent process by allowing genetic patents that may be 
 
 4. 130 S. Ct. 3218 (2010). 
 5. See Diamond v. Diehr, 450 U.S. 175 (1981) (holding that process claims for curing rubber 
were patentable despite including the use of a known equation); Parker v. Flook, 437 U.S. 584 
(1978) (noting that method claims containing algorithms are not patentable); see also MJ Edwards 
& Donald Steinberg, The Implications of Bilski: Patentable Subject Matter in the United States, 
49 IDEA 411, 413 (2009) (noting that “the line between what is patentable and what is not is not 
always clear.  The Supreme Court addressed this line in a series of decisions that are now more 
than twenty-five years old . . .”). Id. 
 6. See Chris Holman, The Impact of Bilski on Biotechnology, HOLMAN’S BIOTECH IP BLOG 
(July 3, 2010, 11:22 AM), http://holmansbiotechipblog.blogspot.com (“[T]he Supreme Court 
provided little if any guidance with respect to what it means for a patent to claim a fundamental 
principle, and absolutely no guidance with respect to how to apply the test when the fundamental 
principle is a biological natural phenomenon . . . .”). 
 7. See Jennifer Giordano-Coltart et al., No Legal Monopoly for Genes: Court Rules Genes 
are Unpatentable Subject Matter, INTELL. PROP. & TECH. L.J. 8, 12 (2010) (discussing the 
uncertainties presented by Supreme Court’s ruling and its chilling effect on genetic research and 
innovation in the medical field). 
 8. See Holman, supra note 6 (suggesting that the Court should draw a line between 
biological phenomena that occur absent human intervention and phenomena that occur as a result 
of human intervention when determining what constitutes patentable subject matter in the genetic 
context). 
 9. See Matthew Herper, Genome Scientists: Gene Patents are Bad, FORBES (June 26, 2002), 
http://www forbes.com/2002/06/26/0626targets html (discussing the balance between gene patents 
and accessibility of information).  For additional information and an overview of the arguments 
for and against gene patenting, see generally HUMAN GENOME PROJECT INFORMATION, Genetics 
and Patenting, http://www.ornl.gov/sci/techresources/Human_Genome/elsi/patents.shtml. (last 
modified July 7, 2010). 
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detrimental to innovation and discovery.10 The courts should protect 
intellectual property while recognizing the patent ineligibility of genetic 
principles and naturally occurring gene sequences. 
I. BASIC GENETIC METHODOLOGIES 
As with many applications, the eligibility of specific discoveries and 
inventions in the field of genetics hinge on a detailed understanding of the 
technical details underlying the application.11 By understanding 
fundamentals of genetics methodologies, the courts can better understand 
whether an application represents a “new and useful process, machine, 
manufacture or composition of matter.”12 
Often described as a double helix, DNA can be conceptualized as a 
twisted zipper that can be opened and closed.13 In this analogy, individual 
chemicals make up the teeth of the DNA zipper.14 When closed, the zipper 
is held together by forces similar to static electricity.15 
Unlike zippers on your clothing, the teeth of DNA zippers come in 
four different types.16 Symbolized by the letters A, C, T and G, the 
 
 10. See Joseph Stiglitz & John Sulston, The Case Against Gene Patents, WALL ST. J., Apr. 
16, 2010, at A19 (stating that genetic patents inhibit access to basic information and may impede 
scientific progress); see also RESNIK, supra note 1, at 202 (stating that “[p]atents on biological 
materials, such as DNA, provide crucial incentives for this developing industry, but they also 
threaten the progress of science, the practice of medicine, the development of agriculture, and the 
preservation of cultural notions concerning the value of human life[]”); see Intellectual Property 
Rights Must be Balanced with Research Needs to Realize Full Potential of Biomedical Research, 
OFFICE OF NEWS AND PUB. INFO. (Nov. 17, 2005), http:// www8 nationalacademies.org/ 
onpinews/newsitem.aspx?RecordID=11487 (emphasizing the need for balance between protecting 
research discoveries and granting access to these discoveries by awarding gene patents to some, 
but not all genomic material). 
 11. See RESNIK, supra note 1, at 40 (noting that in DNA patenting courts require a detailed 
and precise description of the DNA sequence to be patented (citing Regents of the Univ. of Cal. v. 
Eli Lilly & Co., 119 F.3d 1559 (Fed. Cir. 1997))). 
 12. 35 U.S.C. § 101 (2006); see generally Stiglitz & Sulston, supra note 10 (discussing the 
complex nature of gene patents and how the Court’s future decisions should be based upon this 
nature). 
 13. See ALVIN SILVERSTEIN ET AL., DNA 18 (2002) (describing DNA as a zipper); DANIEL 
L. HARTL & ELIZABETH W. JONES, ESSENTIAL GENETICS: A GENOMICS PERSPECTIVE 7 (Lianne 
Ames ed., 3d ed. 2002) (identifying the subunits of DNA as chemical constituents known as 
bases). 
 14. HARTL & JONES, supra note 13, at 7. 
 15. The chemical components of DNA are partnered together by hydrogen bonds, where 
hydrogen atoms on one strand are attracted to electronegative oxygen or nitrogen atoms on the 
other.  See HARTL & JONES, supra note 13, at 215. 
 16. See id. (describing the four bases in DNA as Adenine, Guanine, Thymine and Cytosine).   
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presence of one type of “tooth” on one side of the “zipper” (e.g. an “A”), 
dictates the identity of the tooth on the other side (in this case, a “T”).17 In 
this way, the sequence of teeth on one side of the zipper — the DNA helix 
—determines the sequence on the other side.18 Every time a human cell 
divides, it “unzips” its DNA in order to create two exact replicas of its 
genes, known as its genome.19  
Research and diagnostic techniques take advantage of the zipper-like 
qualities of DNA in order to read the sequence of A’s, T’s, C’s and G’s that 
make up human genes and genomes.20 Methods that “read” patient DNA 
sequences, like genome sequencing and microarrays, help detect specific 
changes in the sequence of the DNA in a patient that may indicate an 
increased risk for a specific disease or condition.21 These techniques do not 
fundamentally alter or transform the DNA sequences that exist in nature;22 
rather the DNA sequence is merely read.23 
To read a patient’s genetic code, DNA is removed from cells through a 
process known as DNA extraction.24 Methods for DNA extraction have 
existed since the 19th century.25 Standard methods purify DNA from 
organisms by breaking open cells and separating the DNA from other 
 
 17. Id. at 7–8. 
 18. See SILVERSTEIN ET AL., supra note 13. 
 19. See id. at 18 (explaining that when DNA replicates, the two sides of the helicase “split 
down the middle at one end, like unzipping a zipper.”); See HARTL & JONES, supra note 13, at 
210 (“The genetic complement of a cell or virus constitutes its genome.”).   
 20. See generally EDWIN H. MCCONKEY, HOW THE HUMAN GENOME WORKS 1–4 (Renee 
Sekerak ed., 2004) (discussing DNA research and diagnostic techniques); see SILVERSTEIN ET 
AL., supra note 13, at 38–39 (discussing the Human Genome Project and the development of 
DNA research). 
 21. See A Brief Guide to Genomics, NAT’L HUMAN GENOME RESEARCH INST. (Aug. 24, 
2010), http://www.genome.gov/18016863 (discussing the importance of genetic research in 
understanding complex diseases and treatments); see also Genetic Testing, GENETICS & PUB. 
POLICY CTR. (May 2006), http://www.dnapolicy.org/science.gt.php (“The results of genetic tests 
can be used to diagnose genetic disease, predict risks of disease, and identify carriers of genetic 
disease” and methods include DNA sequencing and microarrays).   
 22. See generally ROBERT A. BOHRER, A GUIDE TO BIOTECHNOLOGY LAW AND BUSINESS 
27 (2007) (explaining DNA replication techniques); RESNIK, supra note 1, at 26 (noting that while 
DNA replication is a natural process, it can be reproduced under laboratory conditions). 
 23. See BOHRER, supra note 22, at 27 (discussing how sequencing machines read). 
 24. See George Rice, DNA Extraction, MICROBIAL LIFE EDUCATIONAL RESOURCES, 
http://serc.carleton.edu/microbelife/research_methods/genomics/dnaext html (explaining DNA 
extraction). 
 25. Swiss biologist Friedrich Miescher carried out the first successful DNA extraction in 
1868, though it was not until the 1940s that scientists discovered its genetic properties.  See The 
Search for DNA—The Birth of Molecular Biology, BIOTECH. INDUS. ORG. (1990), 
http://www.accessexcellence.org/RC/AB/BC/Search_for_DNA.php. 
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cellular components (e.g. proteins and lipids).26 Importantly, DNA 
extraction procedures do not fundamentally transform the DNA or alter the 
information encoded within it.27 
Microarrays determine whether a patient’s DNA contains a specific 
sequence by matching DNA molecules extracted from patient cells to those 
of a known sequence.28 Microarray chips contain tens of thousands of 
microscopic spots where DNA molecules of known sequence have been 
attached to the surface of the slide.29 After a patient’s DNA is extracted, the 
molecules are “unzipped,” separating the two sides of the DNA helix, and 
tagged with a chemical that glows under laser light.30 The patient’s DNA is 
then placed on a microarray chip.31 Under laboratory conditions, the single-
strand DNA from the patient’s DNA sample will attach to sequences on the 
chip to which it matches.32 After allowing the patient’s DNA to find its 
match on the chip, the chip is observed under a microscope.33 Spots that 
glow indicate sequences that are contained within the patient’s DNA.34 
DNA sequencing allows geneticists to read any portion of a patient’s 
DNA without knowing the sequence in advance.35 Similar to microarrays, 
the process relies on the complementary nature of DNA molecules.36 
However, instead of matching entire DNA molecules to patient DNA, 
 
 26. See RESNIK, supra note 1, at 28 (outlining the process of isolating and purifying DNA). 
 27. See supra note 21 and accompanying text. 
 28. See HARTL & JONES, supra note 13, at 435 discussing microarrays as: 
each containing a different immobilized DNA sequence suitable for hybridization with 
DNA or RNA isolated from cells growing under different conditions, from cells not 
exposed or cells exposed to a drug or toxic chemical, from different stages of 
development, or from different types or stages of a disease such as cancer. 
Id. 
 29. Id. (describing a microarray as a “flat surface about the size of a postage stamp on which 
10,000 –100,000 distinct spots are present . . . .”). 
 30. Id. (describing the variously colored fluorescent labels). 
 31. Id. (“When a sufficient quantity of labeled DNA strands have accumulated, the 
fluorescent samples are mixed and hybridized with the DNA chip.”). 
 32. Id. 
 33. See Patrick O. Brown & David Botstein, Exploring the New World of the Genome with 
DNA Microarrays, 21 NATURE GENETICS SUPPLEMENT 33, 33 (Jan. 1999) (“After hybridization, 
fluorescence measurements are made with a microscope . . . .”). 
 34. Id. 
 35. See T.A. BROWN, DNA SEQUENCING: THE BASICS 3–5 (1994) (outlining the steps of two 
popular methods of reading a patent’s DNA, neither of which require knowing the sequence in 
advance); see also NAT’L HUMAN GENOME RESEARCH INST., supra note 21 (“Sequencing simply 
means determining the exact order of the bases in a strand of DNA.”).     
 36. See LUKE ALPHEY, DNA SEQUENCING: FROM EXPERIMENTAL METHODS TO 
BIOINFORMATICS 5–6  (1997) (referring to the complimentary ability of DNA molecules).   
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sequencing uses unzipped patient DNA as a template to build the 
complementary strand of DNA (i.e. the other side of the DNA zipper) one 
base pair at a time.37 Traditional methods, developed by Fredrick Sanger, 
use procedures that simulate in test tubes the process of DNA replication 
within living cells.38  
Initially, a large number of copies of the region of DNA to be 
sequenced are produced, and in order to read the sequence of these millions 
of identical molecules, sequencing attempts to replicate these DNA 
molecules again.39 However, these reactions periodically incorporate 
specially labeled base pairs (e.g., A’s might be labeled green, T’s red, G’s 
blue and C’s yellow) that terminate the growing DNA strand.40 When 
completed, the reaction results in DNA molecules of every length in the 
sequence.41 For example, if the DNA sequence to be read were GCTA, the 
sequencing reaction would create molecules with the sequences G, GC, 
GCT, and GCTA.42 By putting them through a molecular sieve, these 
molecules can then be separated and arranged based upon size, and then 
visualized to determine their color.43 So if the sequencing reaction creating 
 
 37. See HARTL & JONES, supra note 13 (“[E]ach strand of the double helix serves as a 
template for the synthesis of a new strand . . . .”). 
 38. See F. Sanger & A.R. Coulson, A Rapid Method for Determining Sequences in DNA by 
Primed Synthesis with DNA Polymerase, 94 J. MOL. BIOL. 441, 441 (1975) (describing “[a] 
simple and rapid method for determining nucleotide sequences in single-stranded DNA by primed 
synthesis with DNA polymerase . . . .”); see F. Sanger et al., DNA Sequencing with Chain-
Terminating Inhibitors, 74 PROCE. NAT’L. ACAD. SCI. U.S.A. 5463, 5463–67 (1977) (describing 
DNA sequencing with chain-terminating inhibitors). 
 39. See HARTL & JONES, supra note 13, at 239 (“To obtain the sequence of a long stretch of 
DNA, a set of overlapping fragments must be prepared, the sequence of each is determined, and 
all sequences are then combined.”).  See generally BROWN, supra note 35 (describing the process 
of replicating the DNA molecules through the synthesis of complimentary polynucleotide chains 
from existing single-stranded DNA molecules). 
 40. See BROWN, supra note 35, at 27 (“Strand synthesis is not allowed to continue to 
completion as a chain terminating nucleotide . . . is included in the reaction mixture.”). 
 41. Id. at 4 (“The result is therefore a family of new chains, all of different lengths . . .”); see 
also NAT’L HUMAN GENOME RESEARCH INST., supra note 21 (“Each of the fragments differs in 
length by one base and is marked with a fluorescent tag that identifies the last base of the 
fragment.”). 
 42. See BROWN, supra note 35, at 4–5 (Figure 1.4 illustrates the strand synthesis reaction 
which results in a family of chains with overlapping sequences). 
 43. See HARTL & JONES, supra note 13, at 240 (“The fragments from all four sequencing 
reactions are combined, the fragments are separated by size using electrophoresis in a gel or 
capillary tube, and the dideoxy terminator is identified by its fluorescence.”). 
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molecules that, from smallest to largest, were blue, yellow, red and green, a 
researcher would know the sequence he was interested in read “GCTA.”44 
However, knowing a patient’s DNA sequence is only the beginning.45 
Even a decade after the publication of the first draft of the human genome, 
researchers are only beginning to decipher the exceedingly complex 
language encoded by human DNA.46 
Understanding the language of the human genome is like translating a 
foreign language. The human genome contains approximately 3 billion base 
pairs, which encode approximately 20,000 genes.47 The function of many 
of these genes is poorly understood, if not completely unknown.48 Even 
when a gene’s function is known, it is seldom clear how mutations in that 
DNA sequence will affect a patient’s health.49  
With only a rudimentary understanding of the language of the human 
genome, geneticists seek to connect the individual differences in patients’ 
DNA with their physical traits and diseases.50 But individual people differ 
at thousands of locations in their genomes and have hundreds of different 
 
 44. See id. at 240–41 (illustrating the process through which a DNA sequence can be read 
directly from the colored gel lanes). 
 45. See MCCONKEY, supra note 20, at  4 (“Completion of the human genome sequence is a 
major milestone in human genetics, but it certainly does not mean that we know how all the genes 
function.”); see also SANDY B. PIMROSE, PRINCIPLES OF GENOME ANALYSIS: A GUIDE TO 
MAPPING AND SEQUENCING DNA FROM DIFFERENT ORGANISMS 7 (2d ed. 1998) (“Detailed 
understanding of an organism will only be achieved when every gene has been identified and its 
transcript and the timing of transcript synthesis known.”). 
 46. Geoffrey Carr, Biology 2.0: A Special Report on the Human Genome. THE ECONOMIST, 
June 17th  2010 (“[Researchers] found that their methods for linking genetic variation to disease 
were inadequate…however, these obstacles are falling away.”). 
 47. See NAT’L HUMAN GENOME RESEARCH INST., supra note 21. 
 48. See NAT’L HUMAN GENOME RESEARCH INST., Transcriptome, http: 
//www.genome.gov/13014330 (last reviewed Nov. 26, 2010) (“The function of most genes is not 
yet known.”).     
 49. See MCCONKEY, supra note 20, at 46 (describing how genetic and environmental factors 
both can affect the probability that a clinical condition or disease will develop); see also J. Craig 
Venter et al., The Sequence of the Human Genome, 291 SCIENCE 1304, 1348 (2001) (“The 
sequence is only the first level of understanding of the genome.  All genes and their control 
elements must be identified; their functions, in concert as well as in isolation, defined; their 
sequence variation worldwide described; and the relation between genome variation and specific 
phenotypic characteristics determined.”).   
 50. See NAT’L HUMAN GENOME RESEARCH INST., Structural Variation, 
http://www.genome.gov/25521748 (last reviewed Aug. 24, 2010) (“However, we still do not 
completely understand the ‘normal’ range of human variation present in populations to provide a 
basis for understanding the variations that result in disease.”).     
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physical traits.51  In order to determine the genetic changes that result in a 
given disease or physical trait, geneticists use statistical methods and 
algorithms to compare the DNA of hundreds of people with a disease or 
trait and determine which changes commonly contribute to the disease.52 
By using well-established statistical methods and large numbers of 
patients, geneticists are beginning to identify changes in individuals that 
might lead to a greater susceptibility to a given disease or physical trait.53 
And as technologies advance and the cost of determining an individual’s 
DNA sequence continues to fall, studies that associate disease with 
particular changes in patients’ DNA have become common.54 Many studies 
have focused on rare diseases that are caused by a small number of genetic 
changes.55 Genome Wide Association Studies56 have also sought out the 
genetic changes that influence a person’s risk for complex, common 
diseases like heart disease, obesity, and autism, while trying to understand 
how a patient’s environment may exacerbate or minimize the risk of these 
diseases.57 
 
 51. Lynn B. Jorde & Stephen P. Wooding, Genetic Variation, Classification, and ‘Race,’ 36 
NATURE GENETICS S28, S28 (2004) (“[E]ach pair of humans differs, on average, by two to three 
million base pairs.”);  See NAT’L HUMAN GENOME RESEARCH INST., Genetic Variation Program, 
(“Most of any one person’s DNA, about 99.5 percent, is exactly the same as any unrelated 
person’s DNA.”). 
 52. See generally Richard Mayeux, Mapping the New Frontier: Complex Genetic Disorders, 
115 J. CLIN. INVEST. 6, 1405–8 (2005) (discussing specific methods that geneticists use to identify 
“disease genes”). 
 53. Id. at 1404 (“The remarkable achievements in human genetics over the years have been 
due to technological advances in gene mapping and in statistical methods that relate genetic 
variants to disease.”).  A partial list of DNA-based tests can be found at 
http://www.ornl.gov/sci/techresources/Human_Genome/medicine/genetest.shtml.   HUMAN 
GENOME PROJECT INFO., supra note 9. 
 54. See HUMAN GENOME PROJECT INFO., Facts About Genome Sequencing, 
http://www.ornl.gov/sci/techresources/Human_Genome/faq/seqfacts.shtml (last modified Sept. 19, 
2008) (describing the increase of sequencing output from 200 million base pairs in 1998 to 1.5 
billion bases for the month of January 2003). 
 55. Sarah B. Ng et al., Targeted Capture and Massively Parallel Sequencing of 12 Human 
Exomes, 461 NATURE 272, 272 (2009). 
 56. See NAT’L HUMAN GENOME RESEARCH INST., Genome Wide Association Studies, 
http://www.genome.gov/20019523 (last reviewed Aug. 17, 2010) (“A genome-wide association 
study is an approach that involves rapidly scanning markers across the complete sets of DNA, or 
genomes, of many people to find genetic variations associated with a particular disease.”). 
 57. See Mayeux, supra note 52, at 1404, 1407 (stating that “the challenge now is to dissect 
common complex genetic disorders such as obesity, diabetes, schizophrenia, and cancer” and 
describing the “relatively new field of genetic epidemiology” as studying the joint effects of 
environmental and genetic risk factors related to disease).  
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Once DNA changes associated with specific diseases are known, the 
hope is to sequence new patients’ DNA and predict the types of diseases to 
which a given patient may be susceptible.58 Traditional genetic tests, such 
as Myriad’s BRCA1/2 test for breast/cervical cancer,59 sequence individual 
genes in order to make predictions about a small number of diseases.60 
Other companies attempt to leverage the advances of Genome Wide 
Association studies to predict consumers’ risks of common diseases.61 
However, the direct-to-consumer genetic tests from companies like 
23andMe,62 Navigenics,63 and Pathway Genomics64 have come under 
severe scrutiny recently for giving consumers conflicting predictions about 
their disease risk.65 
II. INTELLECTUAL PROPERTY AND THE GENETICS COMMUNITY 
As technologies and methodologies have progressed, the genetics 
community has embraced a balanced approach to intellectual property, 
protecting invention while promoting the exchange of scientific data and 
discovery.66 For example, the Bayh-Dole Act67 has helped to incentivize 
the application of genetic discoveries to the marketplace by vesting the 
rights to the intellectual property resulting from federally funded research in 
 
 58. See HUMAN GENOME PROJECT INFO., supra note 9 (discussing the hope that after 
technological improvements health professionals will be able to give patients individual 
information regarding their risks of developing specific diseases). 
 59. See RESNIK, supra, note 1, at 159–60 (providing background on Myriad Genetics). 
 60. Id. (describing the BRCA1/2 test). 
 61. See, e.g., DeCODE Your Health, DECODEME, https://www.decodeme.com/complete-
genetic-scan  (offering for sale a complete genetic scan to determine one’s risk to “many of the 
most common diseases” including heart attack, diabetes, and baldness). 
 62. See Andrew Pollack, California Licenses 2 Companies to Offer Gene Services, N.Y. 
TIMES, Aug. 20, 2008, at C3 (describing the services being offered by 23andMe and Navigenics). 
 63. Id.  
 64. See Andrew Pollack, Outlook Uncertain, N.Y. TIMES, Mar. 20, 2010, at B1 (discussing 
the role of Pathway Genetics in the direct-to-consumer genetic testing market). 
 65. U.S. GOV’T ACCOUNTABILITY OFFICE, GAO-10-847T, DIRECT-TO-CONSUMER GENETIC 
TESTS: MISLEADING TEST RESULTS ARE FURTHER COMPLICATED BY DECEPTIVE MARKETING 
AND OTHER QUESTIONABLE PRACTICES, HEARING BEFORE THE SUBCOMM. ON OVERSIGHT AND 
INVESTIGATIONS AND H. COMM. ON ENERGY AND COMMERCE,  4–5 (2010), available at 
http://www.gao.gov/new.items/d10847t.pdf (discussing a special investigation of direct-to-
consumer genetic testing companies that called into question the validity of their services).   
 66. See NAT’L HUMAN GENOME RESEARCH INST., Intellectual Property and Genomics, 
http://www.genome.gov/19016590 (last updated Nov. 16, 2010) (discussing competing interests in 
the genetics community regarding the strength of intellectual property protection). 
 67. 35 U.S.C. §§ 200–12 (2006). 
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the academic institutions that receive the federal grant.68 Many new and 
emerging biotechnology companies are based on proprietary intellectual 
property in genetics,69 and use intellectual property as the basis for 
garnering venture funds for their growth and development.70 
But even as eligibility for patents can incentivize invention and 
innovation,71 excessively designating new discoveries as proprietary may 
also have a chilling effect on research.72 As the human genome project 
accelerated, the genetics community recognized the importance of 
balancing patent rights with the open exchange of scientific data and 
information.73 In 1996, members of the genetics community, including 
 
 68. See RESNIK, supra note 1, at 70 (discussing the history of the Bayh-Dole Act); see also 35 
U.S.C. §§ 200–12 (2006). 
 69. See MICHAEL H. BRODOWSKI ET. AL., BIOTECHNOLOGY AND THE LAW 25 (Eileen Smith 
Ewing and Hugh B. Wellons eds., 2007) (explaining that life science companies depend on patents 
as the foundation of the company); see Bryn Williams-Jones, History of a Gene Patent: Tracing 
the Application and Development of Commercial BRCA Testing, 10 HEALTH L.J. 123, 126 (2002) 
(following the Supreme Court’s decision in Diamond v. Chakarbarty, biotechnology start-up 
companies increased in number between 1992 and 2002 and were largely based on a genetic 
patents). 
 70. See e.g., RESNIK, supra note 1, at 67 (explaining that biotech companies, such as Celera 
Genomics, which spent $200 million on research and development between 1997–2001 without 
making a profit, depended heavily on patents for their development). 
 71. See id. at 70–71 (explaining DNA patents have provided industry with an incentive to 
invest billions annually in basic and applied research, and the importance of the private sector’s 
contribution); Clarisa Long, Patents and Cumulative Innovation, 2 WASH. U. J.L. & POL’Y 229, 
230–31 (2000) (explaining that proprietary intellectual property drive innovation because without 
these rights, inventors would lack incentives to create as they would not be able to recoup the full 
value of their invention); Arti K. Rai, Intellectual Property Rights in Biotechnology: Addressing 
New Technology, 34 WAKE FOREST L. REV. 827, 828–29 (1999) (“Patents promote invention by 
giving individuals a monetary incentive to devote resources to such invention. Without a patent 
right, the inventor might not be able to recoup her investment in a socially valuable, but cheaply 
copied, product.”).  But see Timothy Caulfield, Human Gene Patents: Proof of Problems?, 84 
CHI.-KENT L. REV. 133, 135–36 (2009) (stating there is little empirical evidence that patents are 
required for the innovation process). 
 72. See RESNIK, supra note 1, at 141 (discussing the research community’s aversion to 
sharing data in order to protect intellectual property claims, with empirical evidence, and growing 
trend in the life sciences is to withhold or delay publication of data to allow time for patent 
protection);  see also Bryan Nese, Bilski on Biotech: The Potential for Limiting Negative Impact 
of Gene Patents, 46 CAL. W. L. REV. 137, 155–56 (2009) (discussing how gene patents can cause 
excessive delays in research when scientists must obtain a license to conduct research on patented 
genes or over hesitation to share data in an effort to protect patent eligibility). 
 73. See RESNIK, supra note 1, at 4–5.  In the 1990’s as the Human Genome Project was 
underway, competition between the public and private efforts developed over the issue of public 
access to data.  See id. at 4.  The company Celera Genomics planned to charge institutions a fee to 
access data in advance and to patent portions of the human genome DNA sequences.  See id.  
However, by 2000, Celera and the National Human Genome Research Institute arrived at a 
consensus on data sharing and both published versions of the human genome in scientific journals.  
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members of the human genome project, agreed that human genome 
sequences “should be freely available and in the public domain in order to 
encourage research and development and to maximize its benefit to 
society.”74 These principles formed the basis of the National Human 
Genome Research Institute’s Policy for Release and Database Deposition of 
Sequence Data.75 
Embracing not only patents but also public access, geneticists have led 
the scientific community in the development of publicly accessible 
databases.76 The National Institutes of Health77 (NIH) supports a variety of 
publicly accessible databases for gene sequences and information from 
humans and other organisms.78 For example, dbGaP (database of 
 
See id. at 4–5.  But see Melissa L. Sturges, Who Should Hold Property Rights to the Human 
Genome? An Application of the Common Heritage of Humankind, 13 AM. U. INT'L L. REV. 219, 
237–38 (1997 –1998).  Private companies had several reasons why they felt patent protection was 
necessary to forward research on genome sequences, including the monetary incentive provided 
by patents as a motivation for researchers to complete the human genome sequence faster.  Id. at 
238. 
 74. See HUMAN GENOME PROJECT INFO., Summary of Principles Agreed at the First 
International Strategy Meeting on Human Genome Sequencing, http://www.ornl.gov/sci/ 
techresources/Human_Genome/research/bermuda.shtml (last modified Oct. 29, 2003). 
 75. See NAT’L HUMAN GENOME RESEARCH INST., NHGRI Policy for Release and Database 
Deposition of Sequence Data, http://www.genome.gov/page.cfm?pageID=10000910  (last 
reviewed Aug. 2006).  The National Human Genome Research Institute’s (NHGRI) policy for 
release and deposition of DNA sequence data intended to make genome sequence information 
publically accessible for free within 24 hours of obtaining data 2 kb or larger. Id. 
 76. See, e.g., Bruno J. Stasser, GenBank—Natural History in the 21st Century?, 322 SCIENCE 
537, 537 (2008) (describing the meeting of scientists in March 1979 to develop a national DNA 
sequence database); The First Public Nucleotide Sequence Database Turns 25, EUROPEAN 
MOLECULAR BIOLOGY LAB. (May 22, 2007), http://www.ebi.ac.uk/embl/News/news html 
(explaining the nucleotide sequence database, EMBL-Bank, was the first publically accessible 
database of DNA and RNA sequences); National Institute of Health News, GenBank Celebrates 
25 Years of Service with Two-Day Conference; Leading Scientists Will Discuss the DNA Database 
at April 7-8 Meeting, NIH NEWS (April 3, 2008), http://www nih.gov/news/health/apr2008/nlm-
03 htm (discussing the origination of GenBank, a nucleic acid sequence database, that was created 
by scientists in 1982 as a way for research groups to compare protein and DNA sequencing data). 
 77. The National Institutes of Health (NIH) is federal agency composed of over 27 institutes 
and under the U.S. Department of Health and Human Services.  See About NIH, The Nation’s 
Medical Research Agency, NAT’L INST. OF HEALTH, http://www nih.gov/about/NIHoverview html 
(last updated June 19, 2007).  The NIH is a leading institute in medical and scientific research to 
improve the health of the nation. See id. 
 78. See NLM Databases & Electronic Resources, U.S. NAT’L LIBRARY OF MED., 
http://www.nlm nih.gov/databases/ (last updated Sept. 17, 2010). The National Library of 
Medicine website at the National Institutes of Health contains an alphabetical listing of all of 
NIH’s publically accessible databases, including all the genetic databases.   
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Genotypes and Phenotypes)79 is a publicly accessible, web-based database 
that connects human gene sequences known as genotypes, with their 
associated diseases and conditions, known as phenotypes.80 Data within 
dbGaP are clearly identified as “pre-competitive”81 and the NIH expects 
funded researchers to provide a data sharing plan.82 However, there are 
certain protections of proprietary data, but these exceptions must be 
discussed with the NIH.83 
III. GENETIC PATENTS IN THE COURTS 
The genetics community has sought to foster innovation by balancing 
intellectual property claims with the promotion of public access to research 
data.84 However, the U.S. Patent Office and the courts have, at times, 
extended patent protections to claims that seem to upset this fragile 
balance.85 While there is little doubt about the patentability of new, useful 
 
 79. NAT’L CENTER FOR BIOTECH. INFO., dbGap Genotypes and Phenotypes,  
http://www ncbi nlm nih.gov/gap (last visited Sept. 24, 2010). 
 80. See Matthew D. Mailman et al., The NCBI dbGaP Database of Genotypes and 
Phenotypes, 39 NATURE GENETICS 1181, 1181 (2007) (explaining dbGaP allows for public access 
to large-scale data sets in order to analyze how genetic traits are associated with phenotypic 
disease traits). 
 81. See NAT’L CENTER FOR BIOTECH. INFO., supra note 79 (“The data in dbGaP will be pre-
competitive, and will not be protected by intellectual property patents.”). 
 82. U.S. DEP’T OF HEALTH & HUMAN SERVS., NIH Data Sharing Policy and Implementation 
Guidance: Goals of Data Sharing, http://www.grants.nih.gov/grants/policy/data_ 
sharing/data_sharing_guidance htm (last updated Mar. 5, 2003) (“To facilitate data sharing, 
investigators submitting a research application requesting $500,000 or more of direct costs in any 
single year to NIH on or after October 1, 2003 are expected to include a plan for sharing final 
research data for research purposes, or state why data sharing is not possible.”). 
 83. See id. (“NIH recognizes the need to protect patentable and other proprietary data.  Any 
restrictions on data sharing due to co-funding arrangements should be discussed in the data-
sharing plan section of an application and will be considered by program staff.”). 
 84. See Rebecca S. Eisenberg & Richard R. Nelson, Public vs. Proprietary Science: A 
Fruitful Tension?, 131 DAEDALUS 89, 99 (2002) (explaining the importance of both private and 
public research as private competition encourages more frequent discoveries while free access to 
data allows for free access to genetic information and improves the completeness of proprietary 
databases).  See generally Lori B. Andrews, The Gene Patent Dilemma: Balancing Commercial 
Incentives with Health Needs, 2 HOUS. J. HEALTH L. & POL’Y 65 (2002).  But see, Matthew J. 
Higgins & Stuart J. H. Graham, Balancing Innovation and Access: Patent Challenges Tip the 
Scales, 326 SCIENCE 370, 370 (2009) (proposing that the focus on public access to generic 
pharmaceuticals has tipped the balance “away from the incentives needed to support innovation”). 
 85. See Andrews, supra note 84, at 89–91 (discussing examples of patents that disrupt the 
balance between protecting proprietary rights and the delivery of health care services, such as 
private ownership of the rights to the genetic tests for the Alzheimer’s disease and breast cancer 
genes and each owner’s refusal to let other labs conduct these tests independently). 
      
B  B 
VOL. 6 NO. 1 2011                                                                                 71 
 
and novel machines that carry out genetic methodologies, recent case law 
leaves many questions about the eligibility of genetic processes and the 
genetic material which they utilize.86 
A. Process Claims 
The Supreme Court has consistently ruled that algorithms, mathematical 
formulas and other statistical methodologies, are rarely, if ever eligible for 
patents.87 As discussed above, these methodologies are at the heart of 
genetic diagnostics, associating specific genetic changes with increased risk 
of disease.88 In Gottshalk v. Benson89 and Parker v. Flook,90 the Supreme 
Court ruled that the discovery of new and useful mathematical formulas or 
the application of such formulas is not eligible for patents.91 
In Bilski v. Kappos,92 the Supreme Court maintains this precedent by 
ruling that mathematical algorithm for hedging financial risk is not eligible 
 
 86. See e.g., Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F. 
Supp. 2d 181, 230–31 (S.D.N.Y. 2010) (as amended Apr. 5, 2010) (finding Myriad’s gene patents 
related to the breast cancer genes BRCA1 and 2 invalid because the purified DNA segments 
claimed were not markedly different from that found in nature and were the result of natural 
phenomena); Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 124, 137–38 (2006) 
(Breyer, J., dissenting) (arguing a patent on a process of correlating results to detect vitamin B and 
folic acid deficiencies is invalid because the process is no more than an “unpatentable ‘natural 
phenomenon’”); see also Michael L. Shuster & Juleen Konkel, Of Babies and Bathwater—The 
Impact of In re Bilski on Life Science Patents, 1 HASTINGS SCI. & TECH L.J.153, 154 (2009) 
(reviewing recent cases that help define the scope of patentable subject matter in the life sciences). 
 87. See, e.g., Bilski v. Kappos, 130 S. Ct. 3218, 3231 (2010) (majority opinion) (finding a 
patent on risk hedging ineligible because the concept of hedging is essentially a mathematical 
formula, an unpatentable abstract idea); Diamond v. Diehr, 450 U.S. 175, 185 (1981) (explaining 
“laws of nature, natural phenomena, and abstract ideas” are subject matter excluded from patent 
protection); Diamond v. Chakrabarty, 447 U.S. 303, 309 (1980) (as laws of nature, physical 
phenomena, and abstract ideas have been held not patentable, neither Einstein’s “E=mc2” nor 
Newton’s law of gravity could be found patentable subject matter); see also cases cited infra notes 
89–90 and accompanying text.   
 88. See Mailman et al., supra note 80, at 1185 (describing various statistical methods used to 
ensure high quality genotypic data). 
 89. 409 U.S. 63 (1972). 
 90. 437 U.S. 584 (1978). 
 91. Parker, 437 U.S. at 594 (holding algorithm used for calculating chemical processes 
involved in catalytic conversion was not patent eligible because the algorithm only provided an 
improved method for calculating well known chemical processes); Gottschalk, 409 U.S. at 68 
(holding mathematical formula to convert binary code into binary numbers for use in computers 
was an abstract idea, not a patent eligible process). 
 92. 130 S. Ct. 3218 (2010). 
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for patent.93 However, in concurring with the circuit court’s decision,94 the 
Supreme Court held that a process need not be “tied to a particular machine 
or apparatus”95 or transform “a particular article into a different state of 
thing” in order to be patent eligible.96 Rejecting this “machine or 
transformation test,”97 the Court ruled that the method in question was 
unpatentably abstract and did not pass the non-obviousness criteria.98 
While the decision in Bilski seemingly upholds the precedent that 
mathematical formulas and algorithms are not patentable,99 the Supreme 
Court’s opinion expands the definition of a patent eligible process.100 The 
Court notes that “[p]atents for inventions that did not satisfy the machine-
or-transformation test were rarely granted in earlier eras. . . but times 
change.”101 Struggling to apply patent law to “unforeseen innovations,”102 
the Court notes that it “is unaware of any ‘ordinary, contemporary or 
common meaning,’ of the definitional terms ‘process art or methods’ that 
would require these to be tied to a machine or transform an article.”103 But 
as the Court seeks to expand the definition of a patentable process to meet 
the needs of the information age, it refuses to give guidance on the limits of 
patentable process.104 The Court states: 
 
[T]he patent law faces a great challenge in striking the balance 
between protecting inventors and not granting monopolies over 
 
 93. Id. at 3231 (finding that allowing a patent on hedging financial risk would be the same as 
patenting an abstract idea). 
 94. In re Bilski, 545 F.3d 943 (Fed. Cir. 2008). 
 95. Bilski, 130 S. Ct. at 3325. 
 96. Id.   
 97. See id. at 3227. 
 98. See id. at 3230. 
 99. See id. at 3231 (“The concept of hedging, described in claim 1 and reduced to a 
mathematical formula in claim 4, is an unpatentable abstract idea, just like the algorithms at issue 
in Benson and Flook.”). 
 100. See id. at 3224 (finding that the machine-or-transformation test, which allows patents on 
processes that are linked to a machine or that transform something into a different state,  is not the 
only test for determining patent eligibility); see also William J. Simmons, Bilski v. Kappos: The 
U.S. Supreme Court Broadens Patent Subject-Matter Eligibility, 28 NATURE BIOTECHNOLOGY 
801, 805 (2010) (The Bilksi Court expanded the range of patentable subject matter by “holding 
that the machine-or-transformation test is not the sole test for patent eligibility in the US and the 
types of patent-eligible subject matter are vast.”). 
 101. Bilski, 130 S. Ct. at 3227. 
 102. Id. 
 103. Id. (citing Diamond v. Diehr, 450 U.S. 175, 182 (1981)). 
 104. Simmons, supra note 100, at 805 (2010) (observing that the Court declined to articulate “a 
generic test that would distinguish a patentable method from an abstract idea”). 
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procedures that others would discover by independent, creative 
application of general principles. Nothing in this opinion should 
be read to take a position on where that balance ought to be 
struck.105 
 
By refusing to rule on the limits of process patentability, the Court 
leaves genetic patents in an uncertain state.106 Genetic methodologies, 
including algorithms that associate genetic changes with disease, may be 
poised to revolutionize diagnostics and personalize medicine.107 However, 
excessive granting of patents may have a chilling effect on research, 
limiting the scientific progress that the patents are designed to 
encourage.108 Further, the current uncertainty resulting from the Bilski 
decision may be more problematic because it may lead to the inconsistent 
handling of patents by the courts or the United States Patent and Trademark 
Office (USPTO), and subsequently, years of lawsuits and reluctance from 
investors.109 
By expanding the definition of patentable processes, the Bilski 
decision is immediately relevant to the eligibility of patent claims at issue in 
Prometheus Laboratories, Inc. v. Mayo Collaborative Services.110 The 
patent at issue related to a diagnostic process where a drug was 
administered to a patient and then the patient was tested for the presence of 
a particular chemical, known as a metabolite, that would not have been 
 
 105. Bilski, 130 S. Ct at 3228. 
 106. See Simmons, supra note 100, at 805 (noting the biotech industry’s lack of guidance as to 
what is patentable subject matter under the Court’s Bilski framework for “future innovations such 
as those emerging in the life sciences”). 
 107. See Aleksander S. Popel & Peter J. Hunter, Systems Biology and Physiome Projects, 1 
WILEY INTERDISCIPLINARY REVIEWS: SYS. BIOLOGY AND MED. 153, 153 (2009) (recognizing 
that systems approaches in fields such as genomics and proteomics are poised to revolutionize 
medicine); see also NAT’L HUMAN GENOME RESEARCH INST., Fact Sheet: Genome-Wide 
Association Studies, http://www.genome.gov/20019523 (last reviewed Aug. 17, 2010) (stating that 
genome-wide association studies are laying the foundation for a new era of personalized 
medicine). 
 108. See Stiglitz & Sulston, supra note 10, at A19 (stating that the granting of gene patents 
“not only prevent the use of knowledge in ways that would most benefit society, they may even 
impede scientific progress”). 
 109. See Jonathan Masur, Patent Inflation, 2–3, 5, 33–34 (Chicago Law Sch. Pub. Law & 
Legal Theory Working Paper Grp., Paper No. 316, 2010), available at http:// 
papers.ssrn.com/sol3/papers.cfm?abstract_id=1623929 (anticipating that inconsistent application 
of patents and the uncertainty of patent validity that stems from such application due to decisions 
such as Bilski could lead to the granting of invalid patents which can “hamper a firm’s ability to 
raise capital or write contracts with potential customers”). 
 110. 581 F.3d 1336 (Fed. Cir. 2009); see also infra notes 111–22 and accompanying text. 
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present in the patient in the drug’s absence.111 The patent correlated the 
level of metabolite in the patient with the need to change the drug’s dose in 
order to “minimize [drug] toxicity and maximize efficacy of treatment.”112  
A central issue in the lawsuit concerned whether the patent claims are 
“transformative.”113 While the district court invalidated the patent, arguing 
that the claim represented merely data gathering and mental steps,114 the 
circuit court reversed, arguing that the “claims are to transformative 
methods of treatment, not correlations.”115 
The patent claims in Prometheus are not fundamentally different from 
other diagnostic methods.116 The circuit court argued that that the patents 
are “claims to methods of treatment, which are always transformative” 
when treatments involve drugs administered for the treatment of disease.117 
However, medical practice and diagnosis is inherently empirical, requiring 
the administration of treatments, the evaluation of their efficacy, and the 
adjustment of treatment.118 Many drugs have toxic or undesired side effects 
and a patient’s correct dose can often only be determined by administering 
the drug and testing how the patient responds.119  
If the circuit court’s ruling in Prometheus is allowed to stand under 
Bilski’s expansive and uncertain definition of a patentable process, medical 
diagnostics, including those that use standard genetic methodologies to 
 
 111. Prometheus, 581 F.3d at 1339. 
 112. Id. 
 113. See id. at 1347. 
 114. Id. at 1341. 
 115. Id. at 1349. 
 116. Id. at 1339. See Brian P. Murphy & Daniel P. Murphy, Bilski’s “Machine-or-
Transformation” Test: Uncertain Prognosis for Diagnostic Methods and Personalized Medicine 
Patents, 20 FORDHAM INTELL. PROP. MEDIA & ENT. L.J. 755, 773 (2009) (noting that the 
Prometheus claims for “determining the proper dosage of thiopurine drugs” including the drugs 6-
mercaptopurine and azathiopurine which “have been used for years to treat autoimmune 
diseases”). 
 117. Prometheus, 581 F.3d at 1346. 
 118. See Diederick E. Grobbee, Epidemiology in the Right Direction: The Importance of 
Descriptive Research, 19 EUR. J. OF EPIDEMIOLOGY 741, 741–42 (2004) (explaining that 
empirical documentation of a medical diagnosis requires a study and sampling of cases).   
 119. See Jürgen Brockmöller & Mladen V. Tzvetkov, Pharmacogenetics: Data, Concepts and 
Tools to Improve Drug Discovery and Drug Treatment, 64 EUR. J. CLINICAL PHARMACOLOGY 
133, 139 (2008) (advocating for individualized drug therapy because “the choice of the drug and 
the choice of drug dosing regimens” ought to be “selected based on the patient’s individual 
requirements”); see also William E. Evans & Mary V. Relling, Moving Towards Individualized 
Medicine with Pharmacogenomics, 429 NATURE 464, 464 (2004) (observing that differences in 
DNA sequences means that individuals respond differently to drugs and therefore patients should 
have their proper dosage tested). 
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correlate DNA sequences with specific diseases, may be patentable.120 
Such an expansive definition would likely limit research and access to 
treatment as a select few laid claim to specific genetic associations and their 
clinical applications.121 
B. Claims on Gene Sequences 
Genetic processes often require the use of specific genetic materials, such as 
gene sequences or genetically modified organisms.122 With the accelerated 
progress of the life sciences,123 the courts, Congress, and the USPTO have 
been increasingly willing to grant patents on claims regarding genes and 
living organisms.124 However, because versions of patented sequences exist 
in the DNA of nearly every human being,125 the granting of patents for 
claims of specific gene sequences themselves allows for the patenting of 
naturally occurring phenomena while preventing individuals from knowing 
their own DNA sequences.126  
 
 120. See Jeffrey R. Kuester & Steve D. Perkins, In the Aftermath of Bilski v. Kappos, in 
PATENT LITIGATION 2010, at 20 (PLI Intell. Prop., Course Handbook Ser. No. 24179, 2010) 
(“Although the law remains unsettled, the biotechnology field perhaps enjoys a higher level of 
sympathy.”); see also Wayne A. Keown, Short Circuit: How Will Bilski v. Kappos Inform the 
Federal Circuit on Medical Diagnostic Patents?, PRETI FLAHERTY (June 28, 2010), 
http://www.preti.com/How-will-Bilski-affect-medical-diagnostic-patents (concluding that if 
Prometheus is allowed to stand under Bilski, the considerations will support medical diagnostic 
procedures as patentable subject matter). 
 121. Simmons, supra note 100, at 803 (“Regarding limiting interference with the development 
of nascent technologies, such as biotechnology and biopharmaceuticals, the court indicated that 
some types of inventions ‘raise special problems in terms of vagueness and suspect validity’ and 
could ‘put a chill on creative endeavor and dynamic change.’”). 
 122. BOHRER, supra note 22, at 42 (Carolina Academic Press 2007) (discussing the genetic 
process of a cell and genetically modified organisms). 
 123. See Popel & Hunter, supra note 107, at 153 (“[T]he revolution in biology and progress in 
genomics and proteomics is now beginning to affect medicine.”). 
 124. See Murphy & Murphy, supra note 116, at 759–60 (commenting on the Court’s caution 
“against reading limitations into the patent laws not expressed by the legislature” and that even 
“where an inventor discover[s] a previously unknown natural law or phenomenon” as in some 
diagnostic method claims, there may still be a patentable invention if the application of the natural 
law produces a new and useful end). 
 125. See generally Richard Redon et al., Global Variation in Copy Number in the Human 
Genome, 444 NATURE 444, 444–54 (2006) (noting that gene sequences across individual human 
beings are nearly identical, which means that any patented DNA sequence will exist in most 
human beings). 
 126. See Aykut Çoban, Genomic Information and the Public-Private Imbalance, 2008 
CAPITAL & CLASS 71, 81–82 (stating that the “co-modification and ownership of the components 
of living entities[,]” such as genes and DNA sequences, “through patents raises ethical and legal 
issues”). 
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Recent court cases have expanded traditional interpretations of 
patentable subject matter in order to expand patent protections into the field 
of genetic engineering.127 In Diamond v. Chakrabarty,128 the Supreme 
Court ushered in a new era by ruling that genetically modified organisms 
could be patented.129 Since Chakrabarty, patent law has also begun to 
evolve and now specifically enumerates some of the biotechnological 
processes that are patent eligible, including genetically modified 
organisms.130 
While Congress intended patents to extend to “include anything under 
the sun that is made by man,”131 naturally-occurring DNA sequences 
themselves, as they exist in human beings, fall outside patent eligible claims 
under 35 U.S.C. § 101.132 Despite these prohibitions, patent claims have 
been granted on “isolated” DNA sequences on the basis that isolation of 
DNA from the human body “renders it patentable by transforming it into 
something distinctly different in character.”133 But geneticists are skeptical 
of this false distinction because they recognize that isolating DNA from 
human cells does not fundamentally alter its information content or 
chemical structure.134 The fact that isolated DNA can be reinserted into 
patients and retain its original function is the basis for gene therapy 
research, disease treatments that may soon allow doctors to “fix” parts of a 
 
 127. See Lab. Corp. of Am. Holdings v. Metabolite Labs., Inc., 548 U.S. 125, 125 (2006) 
(dismissing writ of certiorari and maintaining the Federal Circuit court decision ruling that 
Metabolite could patent its discovery of the correlation of amino acid levels with B vitamin levels, 
expanding patent protection to genetic engineering). 
 128. 447 U.S. 303 (1980). 
 129. Id. at 318 (“[U]ntil Congress takes such action, this Court must construe the language of § 
101 as it is. The language of that section fairly embraces respondent’s invention.”). 
 130. 35 U.S.C. § 103(b) (1999). 
 131. See S. REP. NO. 82-1979 (1952); see also SECRETARY’S ADVISORY COMM. ON GENETICS, 
HEALTH, AND SOCIETY, U.S. DEP’T OF HEALTH & HUM. SERVS., GENE PATENTS AND LICENSING 
PRACTICES AND THEIR IMPACT ON PATIENT ACCESS TO GENETIC TESTS 57 (2010) [hereinafter 
SACGHS Report], available at http://oba.od nih.gov/oba/sacghs/reports/SACGHS_ 
patents_report_2010.pdf. 
 132. Ass’n for Molecular Pathology v. U.S. Patent and Trademark Office, 702 F. Supp. 2d 181, 
233–37 (S.D.N.Y. 2010) (finding that the methods of analyzing isolated DNA gene sequences to 
identify mutations relating to breast cancer predisposition were not patentable subject matter 
under the machine-or-transformation test). 
 133. Id. at 185.   
 134. See id. at 199 (“In the context of a gene or a portion of the genome, sequencing is 
designed to illuminate the information that nature has dictated in that person’s genome, and the 
sequencing process, by design, does not alter the information content of the native DNA 
sequence”). 
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patients’ DNA that will cause disease.135 Despite reservations from many 
geneticists, approximately 20% of all human gene sequences have been 
patented.136 
In Ass’n for Molecular Pathology v. United States Patent Office, 
(hereinafter Myriad),137 the United States District Court of Southern New 
York invalidated patents related to the gene sequence of the BRCA1 and 
BRCA2,138 certain versions of which make the women who posses them 
more likely to contract breast and cervical cancer.139 In its ruling, the 
district court found that “isolated DNA containing sequences found in 
nature are unsustainable as a matter of law and are deemed unpatentable 
subject matter under 35 U.S.C. § 101.”140 While the court’s decision may 
have implications for gene patenting as a whole, the court confined its 
ruling to the patents at issue and patents representing other genes remain 
valid.141  
By invalidating the patent claims, the court combined a detailed 
understanding of genetic science with relevant case law.142 The Supreme 
Court has consistently held that “products of nature do not constitute 
patentable subject matter absent a change that results in the creation of a 
fundamentally new product”143 and that “‘purification’ of a natural 
compound, without more, is insufficient to render the product of nature 
patentable.”144 Given the non-transformative and purifying nature of DNA 
 
 135. See Richard C. Mulligan, The Basic Science of Gene Therapy, 260 SCIENCE 926, 926 
(1993) (explaining the methods of gene therapy involve introducing DNA sequences into cells to 
treat human disease). 
 136. See Kyle Jensen and Fiona Murray, Intellectual Property Landscape of the Human 
Genome, 310 SCIENCE 239, 239 (2005) (finding that “nearly 20% of human genes are explicitly 
claims as U.S. IP” and 4,382 of the 23,688 genes in the National Center for Biotechnology 
Information database are patented). 
 137. 702 F. Supp. 2d 181 (S.D.N.Y. 2010) [hereinafter Myriad]. 
 138. Id. at 185. 
 139. Id. at 203 (“Mutations in the BRCA1/2 genes correlate with an increased risk of breast and 
ovarian cancer.”); see also Jeffery P. Struewing et al., The Risk of Cancer Associated with Specific 
Mutations of BRCA1 and BRCA2 Among Ashkenazi Jews, 336 NEW ENG. J. MED. 1401, 1401 
(1997) (“Current estimates of the risk of breast cancer in a woman who carries a BRCA1 or 
BRCA2 mutation . . . range from 76 to 87 percent.”). 
 140. Myriad, 702 F.Supp.2d at 185. 
 141. See id.   
 142. See infra notes 143–46 and accompanying text. 
 143. Myriad, 702 F.Supp.2d at 222. 
 144. Id. at 223. 
      
T G’ A  B 
78   JOURNAL OF BUSINESS & TECHNOLOGY LAW 
 
extraction or sequence-reading processes,145 the Myriad decision affirms 
many genetic researchers’ beliefs that DNA sequences should be publically 
available and is not eligible for patents.146  
Importantly, the court’s ruling also affirms the beliefs that DNA 
sequences contained within the human genome belong to no specific 
individual and should be freely available for all to benefit from.147 Gene 
sequences across individual human beings are nearly identical.148 In fact, 
all human beings have a version of the cancer-related genes at issue in 
Myriad (BRCA1 or BRCA2)149 but only those individuals with slight 
differences are at increased risk for developing breast cancer.150 Therefore, 
the question as phrased by many is “how can any individual or company 
have ownership by means of patent of every person’s gene or sequence at 
that location, whether mutant or normal?”151 
 
 145. DNA extraction involves breaking apart the cell membrane and then precipitating the 
DNA out of the solution. However, these processes do not change or alter the DNA in any way. 
See Peter W. Laird et al., Simplified Mammalian DNA Isolation Procedure, 19 NUCLEIC ACIDS 
RESEARCH 4293, 4293 (1991).  DNA sequencing involves the addition base pairs and then 
cleaving the growing strand in order to determine the sequence of the physically purified single 
strand DNA. The single strand DNA does not change through the process. See BROWN, supra note 
35, at 1–5. 
 146. See Summary of Principles Agreed at the First International Strategy Meeting on Human 
Genome Sequencing, GENOMICS.ENERGY.GOV, (Feb. 25-28, 1996), 
http://www.ornl.gov/sci/techresources/Human_Genome/research/bermuda.shtml (last visited Sept. 
27, 2010) (stating that officials and scientists from around the world met in Bermuda and agreed 
that the human genomic sequence information should be freely available to everyone in order to 
maximize the information's benefit to society). 
 147. See Pilar N. Ossorio, The Human Genome as Common Heritage: Common Sense or Legal 
Nonsense?, 35 J.L. MED. & ETHICS 425, 433–34 (2007) (arguing that since the human genome is 
part of the common heritage of mankind, it should be considered a form of public property); see 
also Melissa Sturges, Comment, Who Should Hold Property Rights to the Human Genome? An 
Application of the Common Heritage of Humankind, 13 AM. U. INT’L L. REV. 219, 249 (1997) 
(explaining that the human genome is the blueprint of mankind and should be reserved for public 
access). 
 148. Richard Redon, et al., Global Variation in Copy Number in the Human Genome, 444 
NATURE 444, 444–54 (2006) (finding only a 12% variance in the genome population from DNA 
collected in Europe, America, Africa, and Asia). 
 149. See BRCA1 and BRCA2: Cancer Risk and Genetic Testing, NAT’L CANCER INST. (May 
29, 2009), http://www.cancer.gov/images/documents/abcb7812-a132-4e78-a532-f002c92fa9b9/ 
Fs3_62.pdf  (“BRCA1 and BRCA2 are human genes that belong to a class of genes known as 
tumor suppressors.”). 
 150. See supra note 140; see also RESNIK,  supra note 1, at 159 (“[M]utations of specific genes 
known as BRCA1 and BRCA2 are associated with an increased risk of breast and ovarian 
cancer.”). 
 151. See Sturges, supra note 147, at 249–50 (explaining that allowing a private company to 
own a patent on the human genome would enable the company to decide what to do with it). 
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Additionally, by invalidating the patents in Myriad,152 the court set a 
precedent that will help to alleviate the potential and actual harms that gene 
patenting has had on scientific and medical discoveries. A recent study by 
an advisory panel to the U.S. Secretary of Health and Human Services 
found that gene patents are hindering the development of new medical 
diagnostic tests while limiting patient access to existing tests.153 Further, 
the panel found “the prospect of patent protection of a genetic research 
discovery does not play a significant role in motivating scientists to conduct 
genetic research.”154 Patents on gene sequences do little to promote 
research and discovery while producing significant problems for patients 
and researchers. 
IV. GENETIC PATENTS AND THE FUTURE OF MEDICINE 
Genetic research will continue to provide voluminous data and scientists 
will gain more understanding of the importance of specific genetic 
sequences.155 Even more important will be the knowledge gained about 
epigenetics (the study of gene expression and control caused by 
mechanisms other than DNA sequence).156 The genetics research 
community is ready to abide by all court rulings and federal policies, but 
confusion remains regarding definitions.157 
 
 152. Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 185 (S.D.N.Y. 2010) (as 
amended April 5, 2010). 
 153. SACGHS Report, supra note 131.  
 154. Id. at 1. 
 155. See A Brief Guide to Genomics,  NAT’L HUMAN GENOME RESEARCH INST. (Aug. 24, 
2010),  
http://www.genome.gov/18016863 (recognizing the vast amount of information provided from the 
Human Genome and HapMap Projects and stating that a better understanding of genetics will be 
important in explaining the role of genes in both health and disease of the human body). 
 156. See Bob Weinhold, Epigenetics: The Science of Change, 114 ENVTL. HEALTH 
PERSPECTIVES 160, 163 (Mar. 2006) (defining epigenetics as “any process that alters gene activity 
without changing the DNA sequence, and leads to modifications that can be transmitted to 
daughter cells” and stating that epigenetic mechanisms have become one of the most important 
considerations for the treatment of cancer). 
 157. See Christopher E. James, The Impact on Agricultural Research by Genetic Material 
Patents and the Need for Clarity and Reform in Patent Law for Genetic Material, 11 DRAKE J. 
AGRIC. L. 253, 260 (2006) (stating that a major factor for genetic researchers confusion of their 
rights, duties, and liability under the patent laws is due to the “lack of definiteness” of the law); 
see also Micheal Risch, Everything is Patentable, 75 TENN. L. REV. 591, 650 (2008) (proposing a 
rule to end the subject matter patentability requirement because of uncertainty in the definition 
and the inability of the USPTO to distinguish subject matter from the other requirements). 
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In determining which patent claims might be eligible for many genetic 
methodologies, technologies, and medicines, Bilski leaves scientists and 
medical professionals with uncertainty about the patentability of their 
inventions and discoveries.158 The continuum of steps required to associate 
a specific DNA sequence with a given disease or trait includes a variety of 
individual and population studies involving both the direct analysis of the 
DNA and the statistical analysis of large data bases.159 However, many of 
these processes are now of questionable patent eligibility.160 Especially as 
courts re-examine the patent eligibility of gene sequences, the genetics 
research community is likely to continue to encourage researchers to share 
both methods and results.161 However, when the USPTO or the courts upset 
the appropriate balance between intellectual property protection and data 
sharing that is necessary for a robust research enterprise,162 the patent 
process will continue to confuse and potentially delay the rapid progress 
being made in genetic medicine.163 
The limits of patentable subject matter will continue to be set through 
case law and the organized human genetics community, as well as 
individual scientists, will continue to be involved both as legal parties and 
 
 158. See e.g., Steve Lohr, Bilski Ruling: The Patent Wars Untouched, N.Y. TIMES BITS BLOG 
(Jun. 28, 2010, 7:31 PM), http://bits.blogs nytimes.com/2010/06/28/bilski-ruling-the-patent-wars-
untouched/ (explaining that as the Supreme Court refused to provide a ‘bright line’ rule for the 
patentability of business methods, the Court’s decision has increased uncertainty benefiting only 
the patent litigator). 
 159. See Mayeux, supra note 52, at 1405 (discussing the procedure, which involves the use of 
genetic markers to find specific DNA sequences within the genome and then scientists determine 
the likelihood those sequences are associated with a particular disease through calculation of the 
odds or lod score). 
 160. See Steven Seidenberg, Supreme Court Finally Rules in Bilski v. Kappos, INSIDE 
COUNSEL, (Aug. 20, 2010), http://www.insidecounsel.com/Issues/2010/September 
/Pages/Supreme-Court-Finally-Rules-in-Bilski-v-Kappos.aspx (noting many other fields beyond 
business methods are at risk of being ruled non patentable as a result of Bilski). 
 161. See SACGHS Report, supra note 131, at 26–27 (recognizing the norm for academic 
scientists to share research results). 
 162. See Lab. Corp. of Am. Holdings v. Metabolite Labs., 548 U.S. 124, 138 (2006) (Breyer, 
J., dissenting) (stating that the Supreme Court should decide a patent case in order to contribute to 
the ongoing debate as to whether the patent system reflects the “‘careful balance’ that ‘the federal 
patent laws . . . embod[y].’”); see also Harvey S. Perlman, Taking the Protection-Access Tradeoff 
Seriously, 53 VAND. L. REV. 1831, 1834 (2000) (recognizing one of the classic rationales for 
intellectual property as finding the proper balance between protection and access in order to 
maximize the research output). 
 163. See generally Bryan Nese, Bilski on Biotech: The Potential for Limiting Negative Impact 
on Gene Patents, 46 CAL. W. L. REV. 137, 155–56 (2009) (explaining that the profitability of gene 
patents can cause researchers to disclose less of their results, and therefore hinder research 
progress, to avoid rejection under the novelty aspect of the patent process). 
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as amici curiae.164 As the courts struggle to keep up with the pace of 
genetic research,165 the best jurisprudence will result from decisions fully 
informed by the best scientific and legal principles.  
 
 
 164. Ass’n for Molecular Pathology v. USPTO, 702 F. Supp. 2d 181, 190–92 (S.D.N.Y. 2010) 
(as amended April 5, 2010) (listing eleven different parties as amicus curiae, including 
organizations and two individuals: Kenneth Chahine PhD and Kevin E. Noonan PhD). 
 165. Ryan M.T. Iwasaka, Note, From Chakrabarty to Chimeras: The Growing Need for 
Evolutionary Biology in Patent Law, 109 YALE L.J. 1505, 1519 (2000) (urging that the slow and 
inconsistent work of the courts and USPTO cannot continue because of the rapid development in 
genetic technology).   
